Organogenesis Holdings Inc.
ORGO · XNASCIK 1661181fmd_066GY6P9WZVG8CQW80QBEWS2E3Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2016 to Sep 30, 2026, 43 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 139 | 199 | 193 | 261 | 338 | 467 | 451 | 433 | 482 | 564 |
| Cost of revenue | 48 | 61 | 69 | 76 | 87 | 114 | 105 | 106 | 116 | – |
| Gross profit | 91 | 137 | 125 | 185 | 251 | 353 | 346 | 327 | 366 | – |
| Research and development | 6 | 9 | 11 | 15 | 20 | 31 | 40 | 44 | 50 | 45 |
| Selling, general and administrative | 93 | 134 | 162 | 200 | 204 | 250 | 284 | 270 | 295 | 326 |
| Total operating expenses | 99 | 143 | 176 | 215 | 224 | 281 | 324 | 421 | 483 | 519 |
| Operating income | (9) | (5) | (52) | (30) | 27 | 72 | 22 | 13 | (1) | 45 |
| Interest expense | 6 | 8 | 11 | 9 | 11 | 7 | 2 | 2 | 2 | (2) |
| Interest and investment income | 0 | 0 | 0 | – | – | – | – | – | – | – |
| Other non-operating income (expense) | (6) | (9) | (13) | (9) | (9) | (9) | (2) | (2) | (2) | 2 |
| Income before taxes | (15) | (15) | (65) | (39) | 18 | 63 | 20 | 10 | (3) | 47 |
| Income tax expense | 0 | (7) | 0 | 0 | 1 | (31) | 5 | 5 | (4) | 10 |
| Net income from continuing operations | (15) | (8) | (65) | (39) | 17 | 94 | 16 | 5 | 1 | 37 |
| Net income | (17) | (8) | (65) | (39) | 17 | 94 | 16 | 5 | 1 | 37 |
| Net income to common shareholders | (0) | (9) | (65) | (39) | 17 | 95 | 16 | 5 | (1) | 20 |